ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models
Suresh Bugide(University of Alabama at Birmingham), Narendra Wajapeyee(University of Alabama at Birmingham)
Cited by 2
Related Papers
HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation
|Cellular Oncology|2016|57
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines
|Molecular Cancer Therapeutics|2009|46